Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
Filing tables
Filing exhibits
- 10-K Annual report
- 4.4 Description of Securities Registered Under Section 12
- 10.8 Form of Intec Pharma LTD. Grant Letter - Section 102
- 10.9 Form of Intec Pharma LTD. 2015 Equity Incentive Plan Notice of Non-qualified Stock Option Award
- 23.1 Consent of Kesselman & Kesselman, Certified Public Accountant (Isr.), Independent Registered Public Accounting Firm, a Member of Pricewaterhousecoopers International Limited
- 31.1 Certification
- 31.2 Certification
- 32.1 Certification
- 32.2 Certification
- Download Excel data file
- View Excel data file
Related press release
Indaptus Therapeutics similar filings
Filing view
External links
Exhibit 32.2
Intec Pharma Ltd.
Certification Pursuant to
18 U.S.C. Section 1350,
as Adopted Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the Annual Report of Intec Pharma Ltd. (the “Company”) on Form 10-K for the period ended December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Nir Sassi, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(a) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
(b) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
/s/ Nir Sassi | |
Nir Sassi Chief Financial Officer |
Date: March 13, 2020